NYSE · CIK 0000010795
BDX BECTON DICKINSON & CO
Insider trading from SEC Form 4. Last filing 12 d ago. Close $183.75 on Oct 9, 2026, +36% from the 52-week low and -4% from the high.
Last 90 days
Net insider value
-$14k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$14k by 1 insider
Insiders on file
23
with a Form 4 at this company
Price and insider trades, last year
BDXOct 9, 2026 · close 183.75
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BECTON DICKINSON & CO, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Michael Feld EVP, Chief Revenue Officer sell | $14k 76 shares | -0% | - | |
| 5Weak | Richard Byrd EVP & President Interventional sell | $106k 459 shares | -6% | - | |
| 17Weak | Richard Byrd EVP & President Interventional sell | $436k 1,940 shares | -21% | - | |
| 26Weak | Bertram L Scott director sell | $160k 700 shares | -2% | - | |
| 36Weak | Jeffrey William Henderson director buy | $350k 1,500 shares | +23% | - | |
| 22Weak | Shana Carol Neal EVP and Chief People Officer sell | $189k 787 shares | -5% | - | |
| 20Weak | David Shan EVP and Chief ISC Officer sell | $120k 500 shares | -8% | - | |
| 21Weak | Michael David Garrison EVP & President, Medical sell | $141k 597 shares | -10% | - | |
| 7Weak | Shana Carol Neal EVP and Chief People Officer sell | $185k 788 shares | -5% | - | |
| 40Moderate | Michael David Garrison EVP & President, Medical sell | $634k 2,838 shares | -32% | - | |
| 22Weak | Shana Carol Neal EVP and Chief People Officer sell | $220k 1,000 shares | -6% | - | |
| 25Weak | Roland Goette EVP and President, EMEA sell | $1.1M 5,121 shares | -18% | - | |
| 30Weak | David Shan EVP and Chief ISC Officer sell | $330k 1,500 shares | -19% | - |
Congressional trades
9 trades in BDX disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Alan Armstrong Senate · R-OK | Purchase | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | Mar 27 / Jul 21 116 days after the trade | eFD |
Thomas H. Kean, Jr. House · R-NJ | Sale | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | May 21 / Jun 18 28 days after the trade | Clerk |
Kevin Hern House · R-OK | Sale | BDX Becton, Dickinson and Company Common Stock | $15k to $50k | Mar 17 / Apr 3 17 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Purchase | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | Jun 17, 2025 / Aug 13, 2025 57 days after the trade | Clerk |
Lisa C. McClain House · R-MI | Sale | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | Jun 24, 2025 / Aug 13, 2025 50 days after the trade | Clerk |
Thomas H. Kean, Jr. House · R-NJ | Purchase | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | May 13, 2025 / Jun 17, 2025 35 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Purchase | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | May 15, 2025 / Jun 9, 2025 25 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Sale | BDX Becton, Dickinson and Company Common Stock | $1,001 to $15k | Apr 8, 2025 / Apr 28, 2025 20 days after the trade | Clerk |
Jefferson Shreve House · R-IN | Sale | BDX Becton, Dickinson and Company Common Stock | $15k to $50k | Mar 5, 2025 / Apr 11, 2025 37 days after the trade | Clerk |
Transactions
The last 90 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Michael Feld EVP, Chief Revenue Officer | SOpen-market sale Common Stock10b5-1 | -76 | $183.70 | $14k | 19,644 | 12 d ago |
| Sep 2, 2026 | Vitor Roque EVP & Chief Financial Officer | FTax withholding Common Stock | -190 | $0.00 | $0 | 8,041 | 38 d ago |
| Mar 26, 2025 | Gregory Hayes director | AGrant or award Common Stock | +796 | $0.00 | $0 | 796 | Mar 27, 2025 |
| Mar 18, 2025 | Richard Byrd EVP & President Interventional | SOpen-market sale Common Stock10b5-1 | -459 | $230.00 | $106k | 6,952 | Mar 19, 2025 |
| Mar 12, 2025 | Richard Byrd EVP & President Interventional | SOpen-market sale Common Stock10b5-1 | -1,940 | $224.91 | $436k | 7,411 | Mar 13, 2025 |
| Mar 1, 2025 | Michael David Garrison EVP & President Medical | FTax withholding Common Stock | -178 | $0.00 | $0 | 5,366 | Mar 4, 2025 |
| Feb 12, 2025 | Bertram L Scott director | SOpen-market sale Common Stock | -700 | $227.99 | $160k | 36,033 | Feb 12, 2025 |
| Feb 10, 2025 | Jeffrey William Henderson director | POpen-market purchase Common Stock | +1,500 | $233.62 | $350k | 8,015 | Feb 10, 2025 |
| Feb 6, 2025 | Carrie L Byington director | AGrant or award Rights to Common Stock Under BD Deferred Compensation Planderivative | +121 | $247.60 | $30k | 1,552 | Feb 7, 2025 |
| Feb 6, 2025 | Christopher Ian Montague Jones director | AGrant or award Rights to Common Stock Under BD Deferred Compensation Planderivative | +222 | $247.60 | $55k | 10,662 | Feb 7, 2025 |
| Jan 28, 2025 | Jeffrey William Henderson director | AGrant or award Common Stock | +930 | $0.00 | $0 | 6,515 | Jan 30, 2025 |
| Jan 28, 2025 | Catherine M Burzik director | AGrant or award Common Stock | +930 | $0.00 | $0 | 14,264 | Jan 30, 2025 |
| Jan 28, 2025 | R Andrew Eckert director | AGrant or award Common Stock | +930 | $0.00 | $0 | 9,170 | Jan 30, 2025 |
| Jan 28, 2025 | Carrie L Byington director | AGrant or award Common Stock | +930 | $0.00 | $0 | 3,834 | Jan 30, 2025 |
| Jan 28, 2025 | Claire Fraser director | AGrant or award Common Stock | +930 | $0.00 | $0 | 24,006 | Jan 30, 2025 |
| Jan 28, 2025 | Christopher Ian Montague Jones director | AGrant or award Common Stock | +930 | $0.00 | $0 | 22,701 | Jan 30, 2025 |
| Jan 28, 2025 | Timothy M Ring director | AGrant or award Common Stock | +930 | $0.00 | $0 | 57,915 | Jan 30, 2025 |
| Jan 28, 2025 | Bertram L Scott director | AGrant or award Common Stock | +930 | $0.00 | $0 | 36,733 | Jan 30, 2025 |
| Jan 28, 2025 | Joanne Waldstreicher director | AGrant or award Common Stock | +930 | $0.00 | $0 | 2,270 | Jan 30, 2025 |
| Jan 28, 2025 | William M Brown director | AGrant or award Common Stock | +930 | $0.00 | $0 | 3,486 | Jan 30, 2025 |
| Jan 21, 2025 | Shana Carol Neal EVP and Chief People Officer | SOpen-market sale Common Stock10b5-1 | -787 | $240.00 | $189k | 15,414 | Jan 22, 2025 |
| Jan 21, 2025 | David Shan EVP and Chief ISC Officer | SOpen-market sale Common Stock10b5-1 | -500 | $240.00 | $120k | 5,741 | Jan 22, 2025 |
| Jan 17, 2025 | Michael David Garrison EVP & President, Medical | SOpen-market sale Common Stock10b5-1 | -597 | $236.51 | $141k | 5,544 | Jan 21, 2025 |
| Nov 18, 2022 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Common Stock10b5-1 | +110 | $0.00 | $0 | 16,862 | Jan 10, 2025 |
| Nov 18, 2022 | Shana Carol Neal EVP and Chief People Officer | FTax withholding Common Stock10b5-1 | -31 | $0.00 | $0 | 16,831 | Jan 10, 2025 |
| Nov 20, 2023 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Common Stock10b5-1 | +110 | $0.00 | $0 | 16,941 | Jan 10, 2025 |
| Nov 20, 2023 | Shana Carol Neal EVP and Chief People Officer | FTax withholding Common Stock10b5-1 | -31 | $0.00 | $0 | 16,910 | Jan 10, 2025 |
| Nov 21, 2024 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Common Stock10b5-1 | +111 | $0.00 | $0 | 17,021 | Jan 10, 2025 |
| Nov 21, 2024 | Shana Carol Neal EVP and Chief People Officer | FTax withholding Common Stock10b5-1 | -32 | $0.00 | $0 | 16,989 | Jan 10, 2025 |
| Jan 7, 2025 | Shana Carol Neal EVP and Chief People Officer | SOpen-market sale Common Stock10b5-1 | -788 | $235.00 | $185k | 16,201 | Jan 10, 2025 |
| Nov 18, 2022 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Rights to Common Stock Under BD Deferred Compensation Planderivative10b5-1 | -110 | $0.00 | $0 | 558 | Jan 10, 2025 |
| Nov 20, 2023 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Rights to Common Stock Under Deferred Compensation Planderivative10b5-1 | -110 | $0.00 | $0 | 448 | Jan 10, 2025 |
| Nov 21, 2024 | Shana Carol Neal EVP and Chief People Officer | MOption exercise Rights to Common Stock Under Deferred Compensation Planderivative10b5-1 | -111 | $0.00 | $0 | 337 | Jan 10, 2025 |
| Jan 3, 2025 | David Shan EVP and Chief ISC Officer | FTax withholding Common Stock | -44 | $0.00 | $0 | 6,241 | Jan 6, 2025 |
| Dec 19, 2024 | Michael David Garrison EVP & President, Medical | SOpen-market sale Common Stock10b5-1 | -2,838 | $223.33 | $634k | 6,141 | Dec 20, 2024 |
| Dec 6, 2024 | Shana Carol Neal EVP and Chief People Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $220.49 | $220k | 16,989 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | MOption exercise Common Stock10b5-1 | +6,995 | $147.68 | $1.0M | 22,489 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | MOption exercise Common Stock10b5-1 | +6,339 | $167.91 | $1.1M | 28,828 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | SOpen-market sale Common Stock10b5-1 | -4,483 | $221.01 | $991k | 24,345 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | DDisposition to issuer Common Stock10b5-1 | -9,490 | $221.01 | $2.1M | 14,855 | Dec 10, 2024 |
| Dec 9, 2024 | Roland Goette EVP and President, EMEA | SOpen-market sale Common Stock10b5-1 | -638 | $219.03 | $140k | 14,217 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | MOption exercise Stock Appreciation Rightsderivative10b5-1 | -6,995 | $0.00 | $0 | 0 | Dec 10, 2024 |
| Dec 6, 2024 | Roland Goette EVP and President, EMEA | MOption exercise Stock Appreciation Rightsderivative10b5-1 | -6,339 | $0.00 | $0 | 0 | Dec 10, 2024 |
| Dec 5, 2024 | David Shan EVP and Chief ISC Officer | SOpen-market sale Common Stock10b5-1 | -1,500 | $220.25 | $330k | 6,285 | Dec 6, 2024 |
| Nov 26, 2024 | Pavan Kumar Mocherla EVP & President, Greater Asia | FTax withholding Common Stock | -25 | $0.00 | $0 | 2,847 | Dec 3, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | AGrant or award Rights to Common Stock Under Deferred Compensation Planderivative | +416 | $0.00 | $0 | 416 | Dec 3, 2024 |
| Nov 26, 2024 | Michael David Garrison EVP & President, Medical | AGrant or award Common Stock | +2,553 | $0.00 | $0 | 7,934 | Nov 29, 2024 |
| Nov 26, 2024 | David Shan EVP and Chief ISC Officer | AGrant or award Common Stock | +1,110 | $0.00 | $0 | 6,803 | Nov 29, 2024 |
| Nov 26, 2024 | Roland Goette EVP and President, EMEA | AGrant or award Common Stock | +944 | $0.00 | $0 | 13,529 | Nov 29, 2024 |
| Nov 26, 2024 | Pavan Kumar Mocherla EVP & President Greater Asia | AGrant or award Common Stock | +875 | $0.00 | $0 | 2,692 | Nov 29, 2024 |
| Nov 26, 2024 | Shana Carol Neal EVP and Chief People Officer | AGrant or award Common Stock | +2,109 | $0.00 | $0 | 18,498 | Nov 29, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | AGrant or award Common Stock | +1,932 | $0.00 | $0 | 6,887 | Nov 29, 2024 |
| Nov 26, 2024 | Thomas E Polen Jr Chairman, CEO and President | AGrant or award Common Stock | +15,539 | $0.00 | $0 | 87,350 | Nov 29, 2024 |
| Nov 26, 2024 | Richard Byrd EVP & President Interventional | AGrant or award Common Stock | +2,220 | $0.00 | $0 | 8,280 | Nov 29, 2024 |
| Nov 26, 2024 | Antoine C Ezell EVP, President Americas & CMO | AGrant or award Common Stock | +1,388 | $0.00 | $0 | 10,708 | Nov 29, 2024 |
| Nov 26, 2024 | Christopher DelOrefice EVP & Chief Financial Officer | AGrant or award Common Stock | +4,884 | $0.00 | $0 | 17,676 | Nov 29, 2024 |
| Nov 26, 2024 | Michael Feld EVP & President, Life Sciences | AGrant or award Common Stock | +2,553 | $0.00 | $0 | 9,190 | Nov 29, 2024 |
| Nov 26, 2024 | Roland Goette EVP and President, EMEA | AGrant or award Common Stock | +2,161 | $0.00 | $0 | 15,690 | Nov 29, 2024 |
| Nov 26, 2024 | Shana Carol Neal EVP and Chief People Officer | FTax withholding Common Stock | -509 | $0.00 | $0 | 17,989 | Nov 29, 2024 |
| Nov 26, 2024 | Antoine C Ezell EVP, President Americas & CMO | AGrant or award Common Stock | +2,619 | $0.00 | $0 | 13,327 | Nov 29, 2024 |
| Nov 26, 2024 | Pavan Kumar Mocherla EVP & President Greater Asia | AGrant or award Common Stock | +180 | $0.00 | $0 | 2,872 | Nov 29, 2024 |
| Nov 26, 2024 | Michael Feld EVP & President, Life Sciences | AGrant or award Stock Appreciated Rightsderivative | +10,004 | $0.00 | $0 | 10,004 | Nov 29, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | AGrant or award Common Stock | +416 | $0.00 | $0 | 7,303 | Nov 29, 2024 |
| Nov 26, 2024 | Thomas E Polen Jr Chairman, CEO and President | AGrant or award Common Stock | +36,585 | $0.00 | $0 | 123,935 | Nov 29, 2024 |
| Nov 26, 2024 | David Shan EVP and Chief ISC Officer | AGrant or award Common Stock | +1,106 | $0.00 | $0 | 7,909 | Nov 29, 2024 |
| Nov 26, 2024 | Richard Byrd EVP & President Interventional | AGrant or award Common Stock | +2,275 | $0.00 | $0 | 10,555 | Nov 29, 2024 |
| Nov 26, 2024 | Michael David Garrison EVP & President, Medical | AGrant or award Common Stock | +2,275 | $0.00 | $0 | 10,209 | Nov 29, 2024 |
| Nov 26, 2024 | Christopher DelOrefice EVP & Chief Financial Officer | AGrant or award Common Stock | +9,015 | $0.00 | $0 | 26,691 | Nov 29, 2024 |
| Nov 26, 2024 | Christopher DelOrefice EVP & Chief Financial Officer | FTax withholding Common Stock | -5,192 | $0.00 | $0 | 21,499 | Nov 29, 2024 |
| Nov 26, 2024 | Roland Goette EVP and President, EMEA | FTax withholding Common Stock | -196 | $0.00 | $0 | 15,494 | Nov 29, 2024 |
| Nov 26, 2024 | David Shan EVP and Chief ISC Officer | FTax withholding Common Stock | -124 | $0.00 | $0 | 7,785 | Nov 29, 2024 |
| Nov 26, 2024 | Pavan Kumar Mocherla EVP & President Greater Asia | FTax withholding Common Stock | -20 | $0.00 | $0 | 2,852 | Nov 29, 2024 |
| Nov 26, 2024 | Michael David Garrison EVP & President, Medical | FTax withholding Common Stock | -1,230 | $0.00 | $0 | 8,979 | Nov 29, 2024 |
| Nov 26, 2024 | Shana Carol Neal EVP and Chief People Officer | AGrant or award Stock Appreciation Rightsderivative | +8,264 | $0.00 | $0 | 8,264 | Nov 29, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | FTax withholding Common Stock | -376 | $0.00 | $0 | 6,927 | Nov 29, 2024 |
| Nov 26, 2024 | Antoine C Ezell EVP, President Americas & CMO | FTax withholding Common Stock | -1,357 | $0.00 | $0 | 11,970 | Nov 29, 2024 |
| Nov 26, 2024 | Thomas E Polen Jr Chairman, CEO and President | FTax withholding Common Stock | -23,564 | $0.00 | $0 | 100,371 | Nov 29, 2024 |
| Nov 26, 2024 | Richard Byrd EVP & President Interventional | FTax withholding Common Stock | -1,204 | $0.00 | $0 | 9,351 | Nov 29, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | AGrant or award Stock Appreciation Rightsderivative | +7,568 | $0.00 | $0 | 7,568 | Nov 29, 2024 |
| Nov 26, 2024 | Pavan Kumar Mocherla EVP & President Greater Asia | AGrant or award Stock Appreciation Rightsderivative | +3,426 | $0.00 | $0 | 3,426 | Nov 29, 2024 |
| Nov 26, 2024 | Thomas E Polen Jr Chairman, CEO and President | AGrant or award Stock Appreciation Rightsderivative | +60,891 | $0.00 | $0 | 60,891 | Nov 29, 2024 |
| Nov 26, 2024 | Michael David Garrison EVP & President, Medical | AGrant or award Stock Appreciation Rightsderivative | +10,004 | $0.00 | $0 | 10,004 | Nov 29, 2024 |
| Nov 26, 2024 | Christopher DelOrefice EVP & Chief Financial Officer | AGrant or award Stock Appreciation Rightsderivative | +19,138 | $0.00 | $0 | 19,138 | Nov 29, 2024 |
| Nov 26, 2024 | David Shan EVP and Chief ISC Officer | AGrant or award Stock Appreciation Rightsderivative | +4,350 | $0.00 | $0 | 4,350 | Nov 29, 2024 |
| Nov 26, 2024 | Antoine C Ezell EVP, President Americas & CMO | AGrant or award Stock Appreciation Rightsderivative | +5,437 | $0.00 | $0 | 5,437 | Nov 29, 2024 |
| Nov 26, 2024 | Richard Byrd EVP & President Interventional | AGrant or award Stock Appreciation Rightsderivative | +8,699 | $0.00 | $0 | 8,699 | Nov 29, 2024 |
| Nov 26, 2024 | Roland Goette EVP and President, EMEA | AGrant or award Stock Appreciation Rightsderivative | +3,697 | $0.00 | $0 | 3,697 | Nov 29, 2024 |
| Nov 26, 2024 | Michelle Quinn EVP and General Counsel | AGrant or award Rights to Common Stock Under Deferred Compensation Planderivative | +416 | $0.00 | $0 | 7,984 | Nov 29, 2024 |
| Nov 5, 2024 | Christopher Ian Montague Jones director | AGrant or award Rights to Common Stock Under BD Deferred Compensation Planderivative | +128 | $233.59 | $30k | 10,392 | Nov 5, 2024 |
| Nov 5, 2024 | Carrie L Byington director | AGrant or award Rights to Common Stock Under BD Deferred Compensation Planderivative | +128 | $233.59 | $30k | 1,424 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Catherine M Burzikdirector
- William M Brownceo, officer, director
- Carrie L Byingtondirector
- Richard ByrdEVP & President Interventional
- Christopher DelOreficeEVP & Chief Financial Officer
- R Andrew Eckertdirector
- Antoine C EzellEVP, President Americas & CMO
- Michael FeldEVP, Chief Revenue Officer
- Claire Fraserdirector
- Michael David GarrisonEVP & President Medical
- Roland GoetteEVP and President, EMEA
- Gregory Hayesdirector, chair, officer
- Jeffrey William Hendersondirector
- Christopher Ian Montague Jonesdirector
- Pavan Kumar MocherlaEVP & President, Greater Asia
- Shana Carol NealEVP and Chief People Officer
- Thomas E Polen JrChairman, CEO and President
- Michelle QuinnEVP and General Counsel
- Timothy M Ringdirector
- Vitor RoqueEVP & Chief Financial Officer
- Bertram L Scottdirector
- David ShanEVP and Chief ISC Officer
- Joanne Waldstreicherdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.